Glenmark is aiming to bolster its burgeoning respiratory presence in Europe by signing an exclusive licensing and marketing agreement with an undisclosed third party for a generic of Boehringer Ingelheim’s Spiriva Handihaler (tiotropium bromide) dry-powder inhaler in Western European markets.
Glenmark is aiming to bolster its burgeoning respiratory presence in Europe by signing an exclusive licensing and marketing agreement with an undisclosed third party for a generic of Boehringer Ingelheim’s Spiriva Handihaler (tiotropium bromide) dry-powder inhaler in Western European markets.
No financial details were disclosed of the deal for the generic treatment of chronic obstructive pulmonary disease (COPD)
One of the biggest biologic loss-of-exclusivity opportunities of the year is almost upon us, as biosimilars developers across the world get ready to launch rivals to Amgen’s denosumab brands Prolia and Xgeva. Generics Bulletin offers a rundown of some of the major contenders and how they view the market.
An executive order from US president Donald Trump aimed at incentivizing domestic manufacturing of critical medicines has been welcomed by the US Association for Accessible Medicines.
The market for biosimilar rivals to Stelara continues to be hotly contested in the US, with partners Teva and Alvotech claiming a boost from an interchangeability designation at the same time as Biocon Biologics highlighted fresh market access agreements.
